The Hindu Business Line : Ranbaxy loses Flomax patent case

Ranbaxy Laboratories will appeal against the ruling of the US District Court of New Jersey in favour of Japanese company, Astellas Pharma Inc. on its generic version of Flomax prostate drug. "We will appeal against the ruling in the Court of Appeals for the Federal Circuit," said a Ranbaxy spokesperson. On Friday, Japan's Astellas had said that it had won its suit filed to prevent Ranbaxy from releasing an early generic version of its Flomax prostate drug. The case had been filed jointly by Astellas and Germany's Boehringer Ingelheim, its US marketing partners for the drug. The drug is prescribed in the treatment of enlarged prostates, and its patent expires in October 2009.

More Stories on : IPR | Pharmaceuticals | Ranbaxy Laboratories Ltd

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Wockhardt Hospitals plans IPO

Madhucon board okays pref issue

RIL board to meet on pref warrants

Ranbaxy loses Flomax patent case

Bata India suspends 180 staff

Bombay Rayon acquires stake in UK co

Budweiser beer to be made in India

Jaiprakash Hydro ties up with PowerGrid

M&A tax benefits should be extended to entire service sector

Premji gets a feel of Suguna Poultry's biz model

Panel moots pruning of interest rates for Dabhol

`Hind Copper net to cross Rs 400 crore'

Wockhardt targets $1-b revenue by 2009

JCB India plans to roll out two more models

Lancor looks to expand in southern property market